Three minutes to identify what hours of observation may miss.
A wrist-worn, AI-enabled diagnostic platform. Non-invasive.
Results in three minutes.
Designed for the emergency department.
A patient arrives with chest pain. The ECG is non-diagnostic. The first troponin draw is ordered. Then the wait begins — 1 hour, 3 hours, sometimes 6 or more — before serial results confirm or exclude high-grade obstruction. During that window, if a severe coronary occlusion is present, heart muscle is dying.
Infrasensor was designed for that window. It delivers an identification result at the moment the patient arrives — not hours later, when the answer finally emerges from the serial protocol.
Placeholder — replacement visual for the serial-troponin wait. Concept TBD.
Infrasensor is a wrist-worn, AI-enabled diagnostic platform designed to identify severe coronary occlusion in approximately three minutes — non-invasively, at the point of care, as an adjunct to standard of care in the emergency department.
Validated across more than 1,500 patients in multicenter clinical studies.
Peer-reviewed publications in Communications Medicine and European Heart Journal – Digital Health.
350-patient FDA pivotal study currently in execution across five U.S. sites.
Content to supply: written permission for public, non-confidential use of each logo. Any logo not cleared in writing is omitted from this strip.
For clinicians
Infrasensor integrates into the earliest moments of the ED encounter.
For health systems
For high-volume emergency departments, the cost of the current ACS observation pathway is measured in boarding hours, bed-days, and throughput drag.
Pursuing Class II De Novo FDA approval — submission anticipated 2026.
Content to supply: a short status paragraph covering where the program stands today — pivotal study enrollment, the sites participating, what remains before submission, and the anticipated review timeline.
Contact